Increased Expression of YKL-40 in Mild and Moderate/Severe Persistent Allergic Rhinitis and its Possible Contribution to Remodeling of Nasal Mucosa

Park, Se Jin; Jun, Young Joon; Kim, Tae Hoon; Jung, Jaebong; Hwang, Gyu Ho; Jung, Kyeong-Ah; Lee, Jun Young; Lee, Heung Man; Lee, Sang Hag

doi:10.2500/ajra.2013.27.3941

Cited by 30 publications

(27 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, the studies conducted so far have failed to find the correlation between YKL-40 and IgE or blood eosinophilia, which is in concordance with our results [25]. The contribution of YKL-40 to the atopic pathomechanisms has been also shown in allergic rhinitis [19]. The expression of YKL-40 was upregulated in epithelial cells in patients with persistent allergic rhinitis.…”

Section: Discussionsupporting

confidence: 91%

See 1 more Smart Citation

Chitinase-3-Like Protein 1 (YKL-40) Reflects the Severity of Symptoms in Atopic Dermatitis

Salomon

Matusiak

Nowicka-Suszko

et al. 2017

Journal of Immunology Research

View full text Add to dashboard Cite

Chitinase-3-like protein 1 (YKL-40) is suggested to be associated with type 2 T helper response and atopy. The aim of the study was the evaluation of serum YKL-40 level in atopic dermatitis. The study was performed on 59 patients: 27 males and 32 females, aged from 18 to 64 years. The severity of the disease was assessed by the SCORAD and objective SCORAD indexes. The severity of pruritus was measured by the visual analogue scale. Blood samples were taken to examine serum level of YKL-40, total IgE level, C-reactive protein level, white blood cell count, and neutrophil count. YKL-40 serum levels were significantly higher in patients with atopic dermatitis compared to the controls. There was a positive correlation between YKL-40 concentration and SCORAD, objective SCORAD, and pruritus. This study has shown that YKL-40 serum level is increased in patients with atopic dermatitis and reflects the severity of symptoms.

show abstract

Section: Discussionsupporting

confidence: 91%

“…Moreover, some reports demonstrate that YKL-40 is associated with atopy and contributes to both innate and adaptive type 2 immune mechanisms [13–16]. This protein has been already evaluated in atopic asthma and rhinitis, demonstrating its role in these diseases [17–19]. That is why we have decided to explore that issue in skin atopy.…”

Section: Introductionmentioning

confidence: 99%

Chitinase-3-Like Protein 1 (YKL-40) Reflects the Severity of Symptoms in Atopic Dermatitis

Salomon

Matusiak

Nowicka-Suszko

et al. 2017

Journal of Immunology Research

View full text Add to dashboard Cite

show abstract

“…Our finding on the association of YKL-40 with MMP-9 is supported by findings in previous in vitro studies. YKL-40 has been shown to stimulate MMP-9 synthesis in BAL alveolar macrophages from smoking COPD patients [42] and in human fibroblasts from nasal mucosa [43]. Moreover, in cultured murine macrophages, YKL-40 has been reported to stimulate MMP-9 expression and inhibition of YKL-40 with siRNA was found to decrease MMP-9 expression [44].…”

Section: Discussionmentioning

confidence: 99%

Glycoprotein YKL-40 Levels in Plasma Are Associated with Fibrotic Changes on HRCT in Asbestos-Exposed Subjects

Väänänen

Lehtimäki

Vuolteenaho

et al. 2017

Mediators of Inflammation

View full text Add to dashboard Cite

YKL-40 is a chitinase-like glycoprotein produced by alternatively activated macrophages that are associated with wound healing and fibrosis. Asbestosis is a chronic asbestos-induced lung disease, in which injury of epithelial cells and activation of alveolar macrophages lead to enhanced collagen production and fibrosis. We studied if YKL-40 is related to inflammation, fibrosis, and/or lung function in subjects exposed to asbestosis. Venous blood samples were collected from 85 men with moderate or heavy occupational asbestos exposure and from 28 healthy, age-matched controls. Levels of plasma YKL-40, CRP, IL-6, adipsin, and MMP-9 were measured with enzyme-linked immunosorbent assay (ELISA). Plasma YKL-40 levels were significantly higher in subjects with asbestosis (n = 19) than in those with no fibrotic findings in HRCT following asbestos exposure (n = 66) or in unexposed healthy controls. In asbestos-exposed subjects, plasma YKL-40 correlated negatively with lung function capacity parameters FVC (Pearson's r −0.259, p = 0.018) and FEV1 (Pearson's r −0.240, p = 0.028) and positively with CRP (Spearman's rho 0.371, p < 0.001), IL-6 (Spearman's rho 0.314, p = 0.003), adipsin (Spearman's rho 0.459, p < 0.001), and MMP-9 (Spearman's rho 0.243, p = 0.025). The present finding suggests YKL-40 as a biomarker associated with fibrosis and inflammation in asbestos-exposed subjects.

show abstract

“…The WAO (World Allergy Organization) also suggest that the preventive benefits of AIT may be greater if initiated early in the course of the allergic disease, and that failure of pharmacological treatment is not an essential prerequisite for the use of AIT [18]. Several studies have reported that both airway remodeling and underlying allergic inflammation exist in patients with mild and moderate-to-severe AR [19,20]. Our study provided new evidence in real life to support the early application of AIT in AR patients, not only for the relief of symptoms but also to possibly improve the clinical response to the AIT itself.…”

Section: Discussionmentioning

confidence: 99%

Early Intervention Improves Clinical Responses to House Dust Mite Immunotherapy in Allergic Rhinitis Patients

Chen

Huang

et al. 2016

Int Arch Allergy Immunol

View full text Add to dashboard Cite

Background: Allergen immunotherapy (AIT) is the unique causal treatment for respiratory allergy. As AIT is expensive and of long duration, the availability of a marker predicting AIT responders is of crucial relevance. Objective: To investigate clinical parameters correlated with effective AIT in allergic rhinitis (AR) patients. Methods: This is a prospective, nonrandomized open study in which a total of 284 AR patients who had received house dust mite (HDM) subcutaneous AIT were enrolled from January 2011 to December 2015, and then followed up for 3 consecutive years. Demographic data, clinical history, laboratory tests (specific and total IgE levels), symptoms score, concomitant medication, and adverse reactions during AIT were collected. An AIT responder patient was defined when a visual analog score (assessing global symptoms) had decreased by >30% compared to baseline and concomitant medication was equal to or less than before AIT. Results: Thirty-three patients dropped out, so 251 patients were analyzed; 175 (69.7%) patients were responders. This group had a higher baseline symptom score than the AIT nonresponder group (7.5 vs. 6.9). A significant negative correlation was found between AR symptom duration and the clinical response to AIT. Local reactions (LRs) during AIT had a positive correlation. Other variables such as a family history of atopy, combined asthma history, and the levels of specific and total IgE had no correlations with effective AIT. Conclusion: Early intervention with AIT helps to improve the efficacy of AR treatment. LRs might predict successful AIT. Highly symptomatic AR patients may develop increased clinical responses to AIT.

show abstract

Increased Expression of YKL-40 in Mild and Moderate/Severe Persistent Allergic Rhinitis and its Possible Contribution to Remodeling of Nasal Mucosa

Abstract: YKL-40 is up-regulated in mild and moderate/severe persistent allergic rhinitis, and its expression can be regulated differentially by different cytokines, possibly contributing to the remodeling of nasal mucosa in allergic rhinitis.

Cited by 30 publications

References 40 publications

Chitinase-3-Like Protein 1 (YKL-40) Reflects the Severity of Symptoms in Atopic Dermatitis

Chitinase-3-Like Protein 1 (YKL-40) Reflects the Severity of Symptoms in Atopic Dermatitis

Glycoprotein YKL-40 Levels in Plasma Are Associated with Fibrotic Changes on HRCT in Asbestos-Exposed Subjects

Early Intervention Improves Clinical Responses to House Dust Mite Immunotherapy in Allergic Rhinitis Patients

Contact Info

Product

Resources

About